- Home
- TRDA
as 09-12-2025 10:19am EST
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 233.5M | IPO Year: | 2021 |
| Target Price: | $25.67 | AVG Volume (30 days): | 223.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.93 - $21.79 | Next Earning Date: | 11-04-2025 |
| Revenue: | $79,476,000 | Revenue Growth: | -66.80% |
| Revenue Growth (this year): | -81.33% | Revenue Growth (next year): | -12.79% |
Latest Entrada Therapeutics Inc. News
TRDA Breaking Stock News: Dive into TRDA Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 months ago
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
GlobeNewswire
3 months ago
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Clinical Trials Arena
3 months ago
Entrada’s Phase I/II trial of DMD treatment authorised to begin in EU
GlobeNewswire
3 months ago
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Simply Wall St.
4 months ago
Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results
Zacks
4 months ago
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
4 months ago
Entrada Therapeutics Reports First Quarter 2025 Financial Results
Zacks
4 months ago
Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Compare TRDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRDA Entrada Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.